Status:
UNKNOWN
Intralesional Vitamin D3 Versus Intralesional Acyclovir in Treatment of Plantar Warts
Lead Sponsor:
Assiut University
Conditions:
Plantar Wart
Eligibility:
All Genders
12-70 years
Phase:
NA
Brief Summary
To evaluate and compare the efficacy and safety of intralesional acyclovir versus intralesional vitamin D3 in the treatment of plantar warts
Detailed Description
Introduction Warts are common epidermal growths caused by various strains of human papillomavirus (HPV) affecting all age groups. They have an unsightly appearance and are mostly asymptomatic but some...
Eligibility Criteria
Inclusion
- Adult participants of both sex with plantar warts will be included in the study
Exclusion
- \- Children \< 12 years.
- Pregnant and lactating women.
- Receiving any treatment for warts within 1 month before the study.
- Systemic antiviral medication.
- Previous history of vitamin D or acyclovir hypersensitivity.
- Vitamin D supplementation.
- Concurrent other skin disorders.
- Immunosuppressive disorders or receiving immunosuppressive drugs.
- Receiving drugs that may alter vitamin D level including prednisone, orlistat, phenytoin and thiazide diuretics.
Key Trial Info
Start Date :
October 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2023
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT05324904
Start Date
October 1 2022
End Date
November 1 2023
Last Update
April 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assuit University
Asyut, Egypt